AEterna Zentaris (NASDAQ: AEZS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AEterna Zentaris (NASDAQ: AEZS)

AEZS 2.720

-11.7%

Sep 3 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ACAN who wrote (13)	3/6/2012 12:59:17 PM
From: caly	Read Replies (1) of 22

This has been an ongoing back and forth for awhile. I have a small position in AEZS of "just in case" shares. seekingalpha.com Mr. Feuerstein presents what he calls the “Feuerstein-Ratain rule” which states that the outcome of phase 3 cancer drug studies can be predicted accurately by looking at the market value of the company running the study. It’s derived from an analysis of 59 phase 3 clinical trials of cancer drugs conducted over the past 10 years. The list of drug trials wasn’t put together by Feuerstein or Ratain, but by a paper published in the Journal of the National Cancer Institute. The study showed that 21 out of 21 phase 3 cancer drug trials for micro-cap companies (companies with less than $300 market cap) failed, whereas 21 of 27 phase 3 trials by the larger companies analyzed (with a greater than $1 billion market cap) were positive. The apparent reason for this disparity is because pharmaceutical stock investors are astute and can accurately predict outcomes of phase 3 trials based on how the phase 1 and 2 trials went.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next